Get WORLDWIDE RELAPSING POLYCHONDRITIS DOCTOR LIST

The outcome of patients with relapsing polychondritis has improved in recent years; survival has increased from 70% at five years to 91% at ten years. The more common clinical presentation is a relatively benign disease, with respiratory failure due to airway collapse being the most common cause of death.

is the drug of choice for relapsing polychondritis (RP) and is used in acute flares and for long-term suppression of inflammation. Continuous treatment with decreases severity, duration, and frequency of relapses.

In over 80% of patients, RP is disclosed by auricular chondritis and polyarthritis, though many organs can be potentially involved. Its onset is often insidious, with acute painful inflammatory crisis followed by spontaneous remission of variable duration.

About Relapsing polychondritis Population Estimate:Fewer than 5,000 people in the U.S. have this disease. Symptoms:May start to appear at any time in life. Cause:GARD does not currently have information about the cause of this condition.

Relapsing polychondritis (RP) causes a systemic inflammatory response that can be fatal without proper care and treatment.

In earlier studies, the 5-year survival rate associated with relapsing polychondritis was reported to be 66%-74% (45% if relapsing polychondritis occurs with systemic vasculitis), with a 10-year survival rate of 55%. More recently, Trentham and Le found a survival rate of 94% at 8 years.

Rheumatologists are doctors trained to diagnose, treat, and manage diseases of inflammation caused when the body's immune system does not work properly. Autoimmune diseases and autoinflammatory diseases are often treated by rheumatologists.

In earlier studies, the 5-year survival rate associated with relapsing polychondritis was reported to be 66%-74% (45% if relapsing polychondritis occurs with systemic vasculitis), with a 10-year survival rate of 55%. More recently, Trentham and Le found a survival rate of 94% at 8 years.